← All trials
NCT04726969
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2021
- Primary completion
- Sep 8, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jan 27, 2021
- Last posted
- Nov 3, 2021
- Enrollment
- 282
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BaselLead sponsor
- University of BaselSponsor investigator
- Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.